表紙
市場調查報告書

液態切片(液態生物檢體)的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Fluid Biopsy Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391417
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
Back to Top
液態切片(液態生物檢體)的全球市場 - 成長,趨勢,預測(2019年∼2024年) Fluid Biopsy Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 113 Pages
簡介

根據WHO的報告,癌症成為在世界上第2大死亡原因。2012年,約有1,400萬人新癌症發病,820萬人因癌症相關原因死亡。液態切片,在固態癌症和主要的診斷中有龐大需求。非小細胞肺癌,頭頸椎癌症,乳癌,惡性淋巴腫瘤,白血病,肝癌等使用液態切片可早期診斷。

本報告提供全球液態切片(液態生物檢體)市場調查,市場概要,各適應症、類型、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 非侵入性手術的需求高漲
    • 世界的癌症病例數的增加
  • 市場阻礙因素
    • 光學切片檢查等替代技術的成長
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各適應症
    • 肺癌
    • 乳癌
    • 大腸癌
    • 其他
  • 各類型
    • 循環腫瘤細胞
    • 循環腫瘤DNA
    • 無細胞DNA
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bio-Rad Laboratories
    • LungLife AI, Inc
    • Inivata Ltd
    • Diagnologix, LLC
    • Exosome Sciences, Inc.
    • Grail, Inc
    • Guardant Health
    • Horizon Discovery
    • Illumina, Inc
    • Qiagen N.V

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55277

Market Overview

Cancer prevalence data indicate the number of people diagnosed with cancer in their lifetime. The key facts stated by WHO estimates that cancer is the second leading cause of mortality across the globe, with around 14 million new cases and 8.2 million cancer-related deaths in 2012, and 8.8 million deaths in 2015. The number of new cases is expected to rise by about 70% in the next two decades. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths, which can be attributed to the aging of the population. The future burden is expected to be even larger, because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries. The demand for early detection of cancer is poised to influence the growth of the global market. Liquid biopsy has been in great demand in the diagnosis of solid and other tumors. Various cancers, such as non-small cell lung carcinoma, head and neck cancer, breast cancer, lymphomas, leukemia, and breast and liver cancer, can be diagnosed early with the help of liquid biopsy. These are the five most common forms of cancer that affect the global population. Lung cancer is the most common variety of cancer, accounting for almost a fifth (17%) of all cases diagnosed. An estimated 6.7 million women worldwide, are believed to have been already diagnosed or bearing a risk of developing breast cancer. Bowel, stomach, and liver cancer have also been common worldwide. The rising incidence of these cancers has therefore promoted and contributed to the growth of the global market, as it is less invasive and more preferable.

Scope of the Report

Fluid biopsy, which is also known as liquid biopsy or fluid phase biopsy, is a procedure of sampling and analyzing non-solid biological tissues (blood and others), for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders.

Key Market Trends

Breast Cancer is Expected to Grow with High CAGR in the Forecasted Period

Breast cancer is the most common cancer among women and is the leading cause of mortality. It accounts for 12% of new cases of cancer being diagnosed every year. Incidence rates vary greatly worldwide. It is increasing, particularly in the developing countries, where a majority of the cases are diagnosed at later stages. Breast cancer is the most commonly diagnosed cancer among American women. About 1 in 8 American women develop invasive breast cancer, over the course of her lifetime. In 2016, an estimated 246,660 new cases of invasive breast cancer and 61,000 new cases of non-invasive (in situ) breast cancer were expected to be diagnosed among women in the United States.

Breast cancer is hormone related. Reproductive factors associated with prolonged exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth, etc. are among the most important risk factors for breast cancer. About 21% of all breast cancer deaths worldwide can be attributed to lifestyle factors, such as alcohol use, obesity, and physical inactivity. Early detection and treatment reduce the mortality rate. A biopsy is the only diagnostic procedure that can definitely determine if the suspicious area is cancerous. Breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested, to check for the presence of breast cancer. Liquid biopsies are a reliable alternative to conventional biopsies, offering a potentially cheaper, easier, and less invasive way of monitoring malignancies. Patients can be tested more frequently. This method provides accurate results, as genetic sequencing of free-floating tumor DNA captures the diversity of genetic alterations found in cancer cells, in different parts of the body, including the primary tumor and metastases. Liquid biopsies could be used to guide cancer treatment decisions. Therefore, these tests are gaining traction, within the diagnostic industry. The fluid biopsy market is expected to boom and the increasing incidences of breast cancer is one of the driving factors for the growth. The various liquid biopsy platforms (circulating tumor cells (CTCs), and cell-free DNA (cfDNA), and exosomes) have shown a potential of adding tremendous value towards the care of breast cancer patients. Colorectal cancer and breast cancer together hold the major share of the fluid biopsy market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In North America region, the United States holds the largest market share and this is due to the fact that the cancer is the second most common cause of death in the United States which has helped the growth of the Fluid Biopsy market in the country.

Competitive Landscape

The Fluid Biopsy market is competitive and consists of a few major players. In terms of market share, these major players currently dominate the market. Some of the major players of the market are Bio-Rad Laboratories, LungLife AI, Inc (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen are among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Non-Invasive Procedures
    • 4.2.2 Increase in the Number of Cancer Cases being Reported Worldwide
  • 4.3 Market Restraints
    • 4.3.1 Growth of Alternative Technologies like Optical Biopsies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Lung Cancer
    • 5.1.2 Breast Cancer
    • 5.1.3 Colorectal
    • 5.1.4 Others
  • 5.2 By Type
    • 5.2.1 Circulating Tumor Cells
    • 5.2.2 Circulating Tumor DNA
    • 5.2.3 Cell-Free DNA
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bio-Rad Laboratories
    • 6.1.2 LungLife AI, Inc
    • 6.1.3 Inivata Ltd
    • 6.1.4 Diagnologix, LLC
    • 6.1.5 Exosome Sciences, Inc.
    • 6.1.6 Grail, Inc
    • 6.1.7 Guardant Health
    • 6.1.8 Horizon Discovery
    • 6.1.9 Illumina, Inc
    • 6.1.10 Qiagen N.V

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top